Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C, Cutts R, Campbell J, Ning J, Fenwick K, Swain A, Brown G, Chua S, Thomas A, Johnston SRD, Ajaz M, Sumpter K, Gillbanks A, Watkins D, Chau I, Popat S, Cunningham D, Turner NC. Pearson A, et al. Among authors: smith nr. Cancer Discov. 2016 Aug;6(8):838-851. doi: 10.1158/2159-8290.CD-15-1246. Epub 2016 May 13. Cancer Discov. 2016. PMID: 27179038 Free PMC article.
Complexity of FGFR signalling in metastatic urothelial cancer.
Rodriguez-Vida A, Saggese M, Hughes S, Rudman S, Chowdhury S, Smith NR, Lawrence P, Rooney C, Dougherty B, Landers D, Kilgour E, Arkenau HT. Rodriguez-Vida A, et al. Among authors: smith nr. J Hematol Oncol. 2015 Oct 24;8:119. doi: 10.1186/s13045-015-0221-6. J Hematol Oncol. 2015. PMID: 26497743 Free PMC article.
Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.
Rooney C, Geh C, Williams V, Heuckmann JM, Menon R, Schneider P, Al-Kadhimi K, Dymond M, Smith NR, Baker D, French T, Smith PD, Harrington EA, Barrett JC, Kilgour E. Rooney C, et al. Among authors: smith nr, smith pd. PLoS One. 2016 Feb 23;11(2):e0149628. doi: 10.1371/journal.pone.0149628. eCollection 2016. PLoS One. 2016. PMID: 26905262 Free PMC article.
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
Paik PK, Shen R, Berger MF, Ferry D, Soria JC, Mathewson A, Rooney C, Smith NR, Cullberg M, Kilgour E, Landers D, Frewer P, Brooks N, André F. Paik PK, et al. Among authors: smith nr. Clin Cancer Res. 2017 Sep 15;23(18):5366-5373. doi: 10.1158/1078-0432.CCR-17-0645. Epub 2017 Jun 14. Clin Cancer Res. 2017. PMID: 28615371 Free PMC article. Clinical Trial.
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
Van Cutsem E, Bang YJ, Mansoor W, Petty RD, Chao Y, Cunningham D, Ferry DR, Smith NR, Frewer P, Ratnayake J, Stockman PK, Kilgour E, Landers D. Van Cutsem E, et al. Among authors: smith nr. Ann Oncol. 2017 Jun 1;28(6):1316-1324. doi: 10.1093/annonc/mdx107. Ann Oncol. 2017. PMID: 29177434 Free article. Clinical Trial.
A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo.
Eberlein C, Kendrew J, McDaid K, Alfred A, Kang JS, Jacobs VN, Ross SJ, Rooney C, Smith NR, Rinkenberger J, Cao A, Churchman A, Marshall JF, Weir HM, Bedian V, Blakey DC, Foltz IN, Barry ST. Eberlein C, et al. Among authors: smith nr. Oncogene. 2013 Sep 12;32(37):4406-16. doi: 10.1038/onc.2012.460. Epub 2012 Oct 29. Oncogene. 2013. PMID: 23108397
Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.
Pommier AJ, Farren M, Patel B, Wappett M, Michopoulos F, Smith NR, Kendrew J, Frith J, Huby R, Eberlein C, Campbell H, Womack C, Smith PD, Robertson J, Morgan S, Critchlow SE, Barry ST. Pommier AJ, et al. Among authors: smith nr, smith pd. Cell Metab. 2016 Jan 12;23(1):77-93. doi: 10.1016/j.cmet.2015.10.015. Epub 2015 Nov 25. Cell Metab. 2016. PMID: 26626460 Free article.
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ. Wedge SR, et al. Among authors: smith nr. Cancer Res. 2005 May 15;65(10):4389-400. doi: 10.1158/0008-5472.CAN-04-4409. Cancer Res. 2005. PMID: 15899831
166 results